OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Haematology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Issue Information	100
e‐Posters	85
Don't forget cord blood in non‐remission acute myeloid leukaemia!	74
Issue Information	68
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	66
Immunophenotypic clustering in paediatric acute myeloid leukaemia	65
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”	56
Issue Information	56
	55
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis	50
The role of genetics in refractory immune thrombocytopenia	49
Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia	47
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	44
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	43
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	40
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	39
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	39
Immune thrombocytopenia (ITP) in pregnancy	38
Empagliflozin modulates CD4⁺ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia	38
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry	36
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	35
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant	34
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	34
Efficacy of ciclosporin monotherapy in non‐severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study	33
Would you like to take some more ruxolitinib after your fedratinib?	33

Indirect presentation of mismatched human leukocyte antigen‐B associates with outcomes of cord blood transplantation	33
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	33
Prolonged platelet hyperactivity after COVID‐19 infection	32
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia	32
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	32
Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing	31
Screening for monoclonal gammopathy of undetermined significance is contraindicated	31